PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease and other neurodegenerative diseases, announced that the UK Medicines and Healthcare Regulatory Agency (MHRA) has granted Clinical Trial Authorisation (CTA) for PharmaKure to commence a muti-ascending dose Phase 2a study to evaluate safety and tolerability of PK051 intended for the treatment of mild cognitive impairment (MCI).
PK051 is an oral combined drug that targets disaggregation of amyloid-β proteins. There is increasing scientific acceptance that overproduction and/or deposition of amyloid-β is the initial event in Alzheimer’s Disease pathology.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!